When the Centers for Medicare & Medicaid Services (CMS) rightly rejected a Massachusetts proposal to restrict Medicaid beneficiaries’ access to prescription drugs last month, it opened the door to much more radical, harmful changes to Medicaid prescription drug coverage. Specifically, it suggested that states could submit proposals drastically limiting drug coverage provided they also leave the federal program that requires drug makers to give states big rebates on prescription drug purchases.